Good Job, MAHA
Unless you make a habit of closely reading nutrition labels—or watching Robert F. Kennedy Jr.'s YouTube channel—you might not realize just how much tartrazine you're ingesting. Kennedy, the U.S. health secretary, is fixated with the chemical, otherwise known as Yellow 5. Many Americans are unknowingly eating this and other 'poisons,' he warned in a YouTube video posted last fall. The lemon-yellow hue tints junk food such as Skittles and Mountain Dew; it's also in chicken bouillon, pancake mix, and pickles. In Europe, products containing Yellow 5 are branded with a label warning that it 'may have an adverse effect on activity and attention in children.' But for two decades, the FDA has declined to ban the dye, citing inconclusive evidence.
Today, the FDA announced that it will move to rid the food supply of Yellow 5 and several other synthetic food dyes, such as Red 40, Blue 1, and Green 3, by the end of next year. It's not a ban: Kennedy, who oversees the FDA, said in a press conference that he has reached an 'understanding' with the food companies to phase out these dyes, although he provided scant details on the specifics. (An HHS spokesperson didn't immediately respond to a request for comment.)
Today's action was, in many ways, a win for Kennedy. Democrats have long grumbled that food companies should not be foisting on Americans chemical-laden versions of products such as Doritos and Froot Loops while selling additive-free versions in other countries. RFK Jr.'s 'Make America Healthy Again' movement has brought Republicans onboard too. In October 2023, California became the first state to ban an artificial food dye, Red 3; it has since been joined by West Virginia, which banned seven dyes this March. In 2025, more than half of the 50 states have introduced similar bills, in some cases specifically shouting out MAHA.
Cracking down on food dyes is a refreshingly modest, incremental step toward reforming America's food system. There is real evidence that these dyes are harmful, particularly to children. A review from 2021 found that 'synthetic food dyes are associated with adverse neurobehavioral effects, such as inattentiveness, hyperactivity and restlessness in sensitive children.' Many children aren't affected by these attention concerns, to be clear, and it's also difficult to pinpoint one dye as worse than another, because they are often studied together. But, as opponents to the dyes have argued, subjecting any proportion of kids to neurobehavioral issues doesn't seem worth having bright-red Skittles.
Moving away from synthetic dyes would be a monumental change for food companies, but they have a reason to cheer for today's news as well. Since states began taking up the food-dye issue in earnest, the industry has complained that differing state laws for food dyes would make it more difficult to run their businesses. In a statement, the Consumer Brands Association, which represents companies such as Nestlé, PepsiCo, and General Mills, said that a 'state patchwork of differing laws creates confusion for consumers, limits access to everyday goods, deters innovation, and increases costs at the grocery store,' and the group maintained that the additives it uses 'have been rigorously studied following an objective science and risk-based evaluation process and have been demonstrated to be safe.' The industry is surely glad to hear that the FDA, at least right now, is not implementing a ban for common dyes such as Yellow 5. 'I believe in love,' FDA Commissioner Marty Makary said today. 'And let's start in a friendly way and see if we can do this without any statutory or regulatory changes.' He added that food companies can use natural dyes such as beet, carrot, and watermelon juice to color their products instead of artificial dyes.
If Kennedy's purported understanding with the food industry falls through and companies balk, Kennedy's and Makary's jobs will become trickier.
The FDA has historically taken years to formally ban just a single food ingredient. It took nearly three years to act on a petition to ban Red 3 in food, despite the fact that scientific studies showed decades ago that the dye causes cancer in rats. At least some of that slowness is by design. Regulators need to document legitimate harm that is caused by these products, and that process can take years. The FDA's job also has become even more difficult in light of the mass layoffs that have played out in the early days of Donald Trump's second presidency. Among the 89 staffers from the FDA's food center are nine people specifically tasked with reviewing additives in foods, according to Jim Jones, a former head of the center. (He resigned in protest of the layoffs in February.)
Either way, the speed with which the food industry phases out these dyes should not be seen as the true measure of just how successful RFK Jr. is. Cracking down on food dyes has become a major plank of the MAHA platform, but the chemicals are nowhere near the biggest impediment to making America healthy again. The true test will be how Kennedy and his movement deals with much more pressing, and intractable, challenges in the American diet. Even without synthetic dyes in our foods, Americans will still overwhelmingly be eating ultra-processed foods loaded with excess sodium and sugar. This doesn't seem to be a point lost on Kennedy, who issued a stern warning today that 'sugar is poison.' And yet, he hasn't articulated any plans to eliminate the ingredient from our food. Phasing out food dyes is easy, at least in comparison with tackling these bigger issues. The real test of the MAHA movement will be not whether it can get the red dye out of Skittles, but whether it can persuade Americans to forgo the Skittles altogether.
Article originally published at The Atlantic
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Journals
an hour ago
- Business Journals
Employers: Use these guidelines to create benefits for the modern workforce
It's impossible to forget the disruption of the COVID-19 pandemic. It reshaped how we live and work, forcing companies to rapidly adapt to remote models and prioritize health and safety in new ways. The crisis made one thing clear for employers: Affordable, meaningful health care benefits are vital — not only for supporting employees but also for ensuring long-term business stability. In the post-pandemic workplace, high-deductible health plans (HDHPs) continue to present challenges, especially for hourly and lower-wage workers. Recruiting and retaining top talent now hinges on offering benefits that go beyond basic coverage — they must be affordable, accessible and relevant. Employers are shifting from cutting costs to investing in benefits that support the whole person. A new framework: Mind, body, money To meet the demands of today's workforce, I use a simple yet powerful framework to guide benefits strategy: Mind, body and money. These three pillars reflect the needs of employees and can help employers design plans that truly make a difference. 1. Mind: Prioritizing mental health Mental health challenges spiked during the pandemic, and they haven't gone away. Today, one in five adults report struggling with mental health, while nearly a third say they don't have a primary care provider (PCP), leading to overall poor well-being. Telehealth has provided a lifeline, but access to in-network mental health providers remains limited. The need for robust mental health support has never been greater, and addressing it must be a priority. 2. Body: Access and prevention Roughly a third of Americans lack a primary care provider (PCP), leading many to rely on urgent care instead. This not only drives up claim volume and employer costs but also increases the risk of chronic conditions going undetected. Consider this: nearly 40% of Americans are pre-diabetic, and managing diabetes can cost $8,000-$10,000 per person annually. For an employer with 50 employees, that could mean $200,000 in preventable expenses. It's critical to ensure employees have access to high-quality preventive care at a price they can afford. Prevention isn't just a health strategy — it's a financial one. 3. Money: Real incentives that work A recent survey by Imagine360 found that 25% of employees would accept a pay cut in exchange for better benefits. That's a powerful signal. But incentives must go beyond surface-level perks like gym memberships. Instead, they should encourage real engagement with health care — rewarding participation in preventive care, screenings and chronic condition management. At the same time, health care costs are climbing fast — especially when it comes to prescriptions. GLP-1 medications are up 200%-300% year over year, prompting employers to reassess pharmacy strategies. Real savings start with aligning incentives to promote smart utilization. The retirement factor Older employees are increasingly delaying retirement — not because they want to, but because they can't afford to stop working. 28% regularly find themselves out of money before payday arrives. 60% of full-time employees are stressed about finances. 56% of financially stressed employees spend three or more hours a week thinking about finances. Consultants must help employers address this early with smart retirement planning tools like 401(k) plans and Health Savings Accounts (HSAs). Financial wellness isn't a separate issue — it's deeply tied to mental and physical health. Supporting employees across all three areas helps ensure smoother, more cost-effective transitions into retirement. Implementing reference-based pricing, a sustainable cost strategy Reference-Based Pricing (RBP) has evolved significantly over the years. What was once viewed as a heavy lift for companies and employees is now gaining momentum as a sustainable solution to out-of-control health care costs, and a great experience for employees. Like HSAs, RBP has continued to garner more adoption — and it's delivering real results. With rising health care 'tariffs,' more employers are turning to RBP to regain control. For example, a nursing home with 800-900 employees implemented RBP and saw health care costs drop by 40%. Four years later, they've maintained those savings, and employees have embraced the model.* RBP is particularly effective for companies with high turnover or low plan engagement. It allows employers to lower deductibles and build a more budget-neutral benefits strategy. While switching any health plan carrier requires change management, the right consultants can guide the process and help ensure both employer and employee success. What consultants must do now It's time for consultants to step up. That means vetting vendors rigorously and recommending only those that align with the employer's core goals — whether it's improving retention, reducing costs or boosting care quality. Employees care deeply about their take-home pay and their health. If a benefit strategy isn't working for them, they'll leave. Strong benefits aren't nice to have — they're a competitive advantage and a critical part of your business strategy. Want to talk about building a smarter benefits strategy that works for your team and your budget? Connect with me on LinkedIn.
Yahoo
2 hours ago
- Yahoo
US Health Secretary Kennedy guts vaccine advisory committee
By Ahmed Aboulenein, Michael Erman and Julie Steenhuysen WASHINGTON (Reuters) -Health Secretary Robert F. Kennedy Jr. has fired all 17 members of a U.S. Centers for Disease Control and Prevention panel of vaccine experts and is in the process of replacing them, his department said on Monday, drawing protest from many vaccine scientists. The move is the most far-reaching in a series of actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine. Scientists and experts said the changes to the vaccine panel, which recommends how vaccines are used and by whom, would undermine public confidence in health agencies. Kennedy promised the move would raise public confidence. "Today we are prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda," Kennedy said in a statement from the Department of Health and Human Services. Kennedy has for years sown doubt about the safety and efficacy of vaccines, but he pledged to maintain the country's existing vaccine standards to secure his appointment in President Donald Trump's administration. The Food and Drug Administration, which is overseen by Kennedy's department, has approved a number of vaccines during his tenure despite concerns over his stances. Even so, at least one senior Republican member of Congress expressed doubts about the changes in the panel. Kennedy said the Advisory Committee on Immunization Practices is rife with conflicts and has never turned down a vaccine, even though the decision to approve vaccines rests with the U.S. Food and Drug Administration. The CDC panel provides guidance to the CDC on which groups of people would most benefit from an already-approved vaccine. "That's a tragedy," said former FDA Chief Scientist Jesse Goodman. "This is a highly professional group of scientists and physicians and others... It's the kind of political meddling that will reduce confidence rather than increase confidence." The Pharmaceutical Research and Manufacturers of America called Kennedy's action concerning for public health. "Upending the ACIP membership increases uncertainty and vaccine skepticism, undermining the health gains achieved through vaccination," the industry body said in a statement late on Monday. Shares of vaccine makers Moderna and U.S.-listed shares of BioNTech fell more than 1%, while Pfizer was down marginally in extended trading on Monday. Kennedy said most panel members receive funding from drugmakers although members are required to declare any potential or perceived conflicts of interest that arise in the course of their tenure and any relevant business interests, positions of authority or other connections with organizations relevant to the committee's work. Kennedy and HHS provided no specific evidence of industry conflicts of interest among departing ACIP members. The CDC's web page for conflicts of interest, last updated in March, showed that one current member had recused herself from votes on a handful of vaccines because she had worked on clinical trials for their manufacturers. BIDEN APPOINTEES All 17 ACIP members were appointed under former President Joe Biden's administration, including 13 in 2024, HHS said. Without their removal, Trump's administration would not have been able to choose a majority of the committee until 2028. "This is not a political committee, it's never been partisan," said Dorit Reiss, a vaccine law expert at UC Law San Francisco. "It's an expert committee. Presidents have never been involved in ACIP membership." The decision drew criticism from Democrats in Congress, and one key Republican expressed concern. "Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion," said Republican U.S. Senator Bill Cassidy in a post on X. "I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case." Cassidy, a doctor from Louisiana who had expressed wariness about Kennedy's anti-vaccine views before clearing the path for him to become the nation's top health official, said at the time he had received assurances Kennedy would protect existing vaccination programs. The CDC panel will convene its next meeting June 25-27 at CDC headquarters in Atlanta, the department said. Vetting new panel members typically takes months, said one expert with close ties to the committee, who expressed doubts the newly appointed panel would be able to meet on time unless Kennedy and his team "have been working in the shadows" to onboard them months ahead of the announcement. Kennedy has drawn condemnation from health officials for his vaccine policies including what they say is a weak endorsement of the measles shots during an outbreak that has infected more than 1,000 mostly unvaccinated people and killed three. He announced last month the government was dropping its recommendation that healthy children and pregnant women should receive COVID shots, sidestepping the typical process. Traditionally, once the FDA approves vaccines for sale to the public, ACIP's role is to review data in a public meeting and vote on vaccine recommendations, which are then sent to the CDC director to sign off. The Affordable Care Act generally requires insurers to cover vaccines that are listed on the CDC vaccine schedules for adults and children. The recommendations also determine which vaccines the CDC's Vaccines for Children program will provide free of charge to those without insurance.
Yahoo
3 hours ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.